FDA
-
-
-
-
-
-
-
XBiotech (XBIT) IND for Natrunix Study Cleared by FDA
-
-
-
-
-
-
-
XBiotech (XBIT) announces COVID-19 candidate True Human antibody therapy may also be used for treating COVID-19 mutant virus
-
-
-
-
-
-
-
Convalescent Plasma Stocks Surge as FDA Issue Emergency Use Authorization
-
-
-
-
-
-
-
XBiotech Announces First Patient Enrolled in Randomized Multi-Center Clinical Study Evaluating Bermekimab Therapy in Patients with Hidradenitis Suppurativa
-
-
-
-
-
-
-
XBiotech Announces Plan to Launch Randomized Phase 2b Study of Bermekimab in Hidradenitis Suppurativa
-
-
-
-
-
-
-
XBiotech (XBIT) Announces Bermekimab Successfully Treats Hidradenitis Suppurativa
-
-
-
-
-
-
-
XBiotech Highlights Third Quarter Developments for 2018
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

